Document is current
Any future updates will be listed below
-
Authors
Coulton, Alexander http://orcid.org/0000-0002-0826-5009
Murai, Jun http://orcid.org/0000-0002-1322-0796
Qian, Danwen http://orcid.org/0000-0002-6209-0764
Thakkar, Krupa
Lewis, Claire E. http://orcid.org/0000-0003-1938-9530
Litchfield, Kevin http://orcid.org/0000-0002-3725-0914
- License Information
-
More Information
Article History
Received: 27 February 2023
Accepted: 24 June 2024
First Online: 6 July 2024
Competing interests
: K.L. has the following disclosures (all unrelated to the current work): patent on indel burden and CPI response pending, patent on ctDNA minimal residual disease calling methods, patent pending on a lung cancer vaccine; speaker fees from Roche tissue diagnostics and Ellipses pharma; research funding from CRUK TDL/Ono/LifeArc alliance and Genesis Therapeutics; and consulting roles with Monopteros Therapeutics, Saga diagnostics, Kynos Therapeutics and Tempus Labs, Inc. Again unrelated to this work, K.L. is currently employed by Isomorphic Labs. J.M. is an employee of Ono Pharmaceutical. The other authors declare no competing interests.
